share_log

Cannara Biotech Reports 51% YoY Revenue Increase In Q2, Wider Net Loss

Cannara Biotech Reports 51% YoY Revenue Increase In Q2, Wider Net Loss

Cannara Biotech报告第二季度收入同比增长51%,净亏损扩大
Benzinga ·  05/01 15:45

Cannara Biotech Inc. (TSXV:LOVE) (OTCQB:LOVFF) (FRA: 8CB0) announced its fiscal second quarter 2024 financial and operating results for the three and six-month periods ended Feb. 29, 2024.

坎纳拉生物技术公司(多伦多证券交易所股票代码:LOVE)(OTCQB: LOVFF)(FRA:8CB0)公布了截至2024年2月29日的三个月和六个月的2024年第二财季财务和经营业绩。

The company reported a 68% year-over-year increase in revenues for the first half of fiscal 2024, a metrics CFO Nicholas Sosiak called "a testament to our growing influence in the Quebec, Ontario, Alberta, and BC markets."

该公司报告称,2024财年上半年的收入同比增长68%,首席财务官尼古拉斯·索西亚克称这一指标 “证明了我们在魁北克、安大略省、艾伯塔省和不列颠哥伦比亚省市场的影响力越来越大”。

"Our proactive steps towards streamlining assets align with our ambition to fortify our financial foundation as we relentlessly stay focused on gaining market share and becoming the leader in Canada, the second-largest cannabis market in the world," Sosiak said. "As for our long-term vision, we do see our future extend beyond our borders where Cannara is a globally recognized brand synonymous with excellence and value in cannabis."

索西亚克说:“我们在精简资产方面的积极举措符合我们巩固财务基础的雄心,因为我们坚持不懈地专注于增加市场份额,成为世界第二大大大麻市场的加拿大的领导者。”“至于我们的长期愿景,我们确实认为我们的未来超越国界,Cannara是全球认可的品牌,是大麻领域卓越和价值的代名词。”

If you are interested in the financial outcomes of the cannabis industry, then you might be interested in attending Benzinga's New Jersey Market Spotlight on June 17. Network with key industry players, hear from the top operators, and close deals that will shape the future. Act now— spots are filling fast. Get your tickets here.

如果您对大麻行业的财务业绩感兴趣,那么您可能有兴趣参加6月17日Benzinga的 “新泽西市场聚光灯”。与主要行业参与者建立联系,听取顶级运营商的意见,并达成将塑造未来的交易。立即行动——空位很快就填满了。在这里获取门票。

Q2 2024 Financial Results

2024 年第二季度财务业绩

  • Total net revenue amounted to CA$19.7 million ($14.4 million) up from CA$13 million in the prior year's period.
  • Gross profit before value adjustments totaled CA$7.1 million, up from CA$4 million in the second quarter of fiscal 2023.
  • Operating expenses totaled CA$6.1 million, up from CA$3.6 million in 2022.
  • Net loss was CA$3.4 million, compared to CA$618,055 net loss in the prior year's period.
  • Adjusted EBITDA came in positive at CA$3.5 million, representing a twelfth consecutive quarter of positive Adjusted EBITDA, compared to an adjusted EBITDA gain of CA$3.2 million in the second quarter of 2022.
  • 总净收入为1,970万加元(合1440万美元),高于去年同期的1,300万加元。
  • 价值调整前的毛利总额为710万加元,高于2023财年第二季度的400万加元。
  • 运营支出总额为610万加元,高于2022年的360万加元。
  • 净亏损为340万加元,而去年同期的净亏损为618,055加元。
  • 调整后的息税折旧摊销前利润为正数,为350万加元,这是连续第12个季度调整后的息税折旧摊销前利润为正,而2022年第二季度调整后的息税折旧摊销前利润增长为320万加元。

FY 2024 Financial Highlights

2024 财年财务摘要

  • Total revenues amounted to CA$39.1 million, up from CA$23.3 million in the first half of fiscal 2023.
  • Gross profit before value adjustments was CA$15 million, up from CA$8 million in the six months ended Feb. 28.
  • Operating expenses totaled CA$10.9 million, up from CA$7.3 million in the prior year's period.
  • Net loss was CA$1.3 million, compared to CA$615,104 net loss in the first half of last year.
  • Adjusted EBITDA came in positive at CA$8.7 million, up from roughly CA$5 million adjusted EBITDA gain in the first half of 2022.
  • As of Feb. 29, 2024, the company had CA$145.8 million in total assets, up from CA$141.5 million as of Aug. 31, 2023.
  • Total current liabilities amounted to CA$60 million as of Feb. 29, up from CA$21.2 million as of Aug. 31, 2023.
  • 总收入为3,910万加元,高于2023财年上半年的2330万加元。
  • 价值调整前的毛利为1500万加元,高于截至2月28日的六个月中的800万加元。
  • 运营支出总额为1,090万加元,高于去年同期的730万加元。
  • 净亏损为130万加元,而去年上半年的净亏损为615,104加元。
  • 调整后的息税折旧摊销前利润为正数,为870万加元,高于2022年上半年调整后的息税折旧摊销前利润增长约500万加元。
  • 截至2024年2月29日,该公司的总资产为1.458亿加元,高于截至2023年8月31日的1.415亿加元。
  • 截至2月29日,流动负债总额为6000万加元,高于截至2023年8月31日的2,120万加元。

Related News

相关新闻

  • Cannara Biotech Q1 Results: Revenue, Net Income And Market Share Up, Quarter Also Marks Company's First Export Sale
  • Olymbec Investments Increases Its Ownership In Cannara Biotech
  • Cannara Biotech Q2 FY23 Revenue Grows 76% YoY To $9.6M, Here Are The Details
  • Cannara Biotech Secures An Additional $10M In Non-Dilutive Capital With Its Lead Credit Provider, BMO Commercial Banking
  • Cannara Biotech第一季度业绩:收入、净收入和市场份额均有所增长,该季度也是该公司的首次出口销售
  • 奥林贝克投资增加了其在坎纳拉生物技术公司的所有权
  • Cannara Biotech23财年第二季度收入同比增长76%,达到960万美元,以下是详细信息
  • Cannara Biotech通过其主要信贷提供商BMO商业银行额外获得1000万美元的非稀释资本
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发